 PITTSBURGH, Feb. 02, 2021 GLOBE NEWSWIRE -- Krystal Biotech Inc. NASDAQ: KRYS the Company, the leader in redosable gene therapies for rare diseases, today announced that it has priced the previously announced underwritten public offering of 1,923,077 shares of its common stock, at a public offering price of 65.00 per share. The Company granted the underwriters a 30-day option to purchase up to an additional 288,461 shares of its common stock. The gross proceeds to the Company from this offering are expected to be approximately 125 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is expected to close on or about February 5, 2021, subject to satisfaction of customary closing conditions. 